Am J Transplant, Volume 5, Suppl 3 Archives - Page 17 of 170 - ATC Abstracts

2015 American Transplant Congress
Everolimus Versus Mycophenolate for Recipients of Kidney Transplants from Expanded Criteria Donors (ECD) Receiving Anti-Thymocyte Globulin and Tacrolimus
H. Tedesco-Silva,¹ C. Felipe,¹ A. Ferreira,¹ M. Cristelli,¹ A. Bessa,¹ P. Ueno,¹ T. Sandes- Freitas,¹ G. Bassos,¹ W. Aguiar,² H. Proença,³ J. Medina-Pestana.¹
¹Nephrology, Hospital do Rim UNIFESP, Sao Paulo, Brazil; ²Urology, Hospital do Rim UNIFESP, Sao Paulo, Brazil; ³Pathology, UNIFESP, Sao Paulo, Brazil.
Introduction: Recipients of kidneys recovered from expanded criteria donors are at higher risk to develop delayed graft function (DGF) and acute rejection (AR), leading to…
2015 American Transplant Congress
Belatacept Based Immunosuppression and Incidence of Proteinuria in Kidney Transplant Recipients
R. Villicana, A. Peng, J. Kahwaji, J. Choi, A. Vo, S. Jordan.
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: Abatacept which is a co-stimulation inhibitor has been suggested to have B7-1 mediated antiproteinuric effects. Belatacept which is another co-stimulation agent has been approved…
2015 American Transplant Congress
IL-21 Regulates Creation of Tertiary Lymphoid Organs in Chronic Allograft Rejection
C. Baum,¹ M. Khattar,² P. Schroder,¹ W. Chen,³ S. Stepkowski.¹
¹Medical Microbiology and Immunology, University of Toledo College of Medicine, Toledo, OH; ²Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Boston, MA; ³Transplant Immunology Research Program, Houston Methodist Research Institute, Houston, TX.
BACKGROUND: IL-21 is a cytokine expressed almost exclusively by cells of the adaptive immune system. This makes it an attractive target for reducing chronic allograft…
2015 American Transplant Congress
Clinical and Immunological Update 15 Years After the First VCA – Subsequent Kidney Transplantation After a Bilateral Hand Transplant
A. Weissenbacher,¹ G. Pierer,² M. Gabl,³ M. Ninkovic,¹ T. Hautz,¹ J. Grahammer,¹ B. Zelger,⁴ B. Zelger,⁵ G. Brandacher,⁶ S. Schneeberger.¹
¹Department of Visceral, Transplant and Thoracic Surgery, Innsbruck Medical University, Innsbruck, Austria; ²Department of Plastic, Reconstructive and Aesthetic Surgery, Innsbruck Medical University, Innsbruck, Austria; ³Department of Traumatology, Innsbruck Medical University, Innsbruck, Austria; ⁴Department of Dermatology and Venerology, Innsbruck Medical University, Innsbruck, Austria; ⁵Institute of Pathology, Innsbruck Medical University, Innsbruck, Austria; ⁶Department of Plastic and Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
Background: We herein describe the long term outcome with emphasis on function, immunosuppression (IS), complication and side effects, histomorphology and graft vascular changes 15 years…
2015 American Transplant Congress
Successful Management of Post Transplant Focal Segmental Glomerulosclerosis With Plasma Exchange and Rituximab
K. Koutroutsos,¹ R. Charif,¹ C. Roufosse,² J. Galliford,¹ D. Taube,¹ M. Loucaidou.¹
¹Kidney and Transplant Centre, Imperial Healthcare NHS Trust, London, United Kingdom; ²Department of Histopathology, Imperial Healthcare NHS Trust, London, United Kingdom.
Background: Post-transplant Focal Segmental Glomerulosclerosis (FSGS) is associated with renal allograft loss. Currently, optimal treatment remains controversial. We propose a management protocol that includes treatment…
2015 American Transplant Congress
Molecular Correlates of Atrophy-Fibrosis in Human Kidney Transplants Provides a New Model of Renal Fibrosis
J. Venner, K. Famulski, P. Halloran.
University of Alberta, Edmonton, Canada.
We studied the effect of time post-transplant on atrophy-fibrosis (AF) and the molecular associations with AF in 703 kidney transplant indication biopsies (bx) 3 days…
2015 American Transplant Congress
Combination of Non-HLA and HLA-DSA Antibodies Identifies Liver Transplants Recipients With Highest Risk for Fibrosis Progression and Mortality
J. O'Leary,¹ J. Cai,² H. Heidecke,³ L. Jennings,¹ A. Philippe,⁴ V. Harbour,¹ R. Catar,⁴ P. Terasaki,² G. Klintmalm,¹ D. Dragun.⁴
¹Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX; ²Terasaki Foundation Laboratory, Los Angeles, CA; ³Celltrend, Berlin, Germany; ⁴Nephrology & Intensive Care Medicine, Charite Berlin, Berlin, Germany.
Recent data has shown an increased risk of fibrosis progression in HCV viremic liver transplant (LT) recipients with HLA DSA in serum. However, the role…
2015 American Transplant Congress
Deficiency of Naturally Occurring Anti-Angiogenic Antibodies Associate With the Development of Metastatic Cancer Post Renal Transplantation and Patient Death
R. Carroll,¹ A. Phillippe,² R. Catar,² H. Heidecke,² D. Dragun.²
¹Central Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, SA, Australia; ²Centre for Cardiovascular Research, Charite Hospital, Berlin, Germany.
We assessed the presence of naturally occurring blocking antibodies to mediators of vascularisation and metastasis in Kidney Transplant Recipients (KTR) with metastatic cancer (n=11), non…
2015 American Transplant Congress
Kidney Plasmacytoid Dendritic Cells Display Distinct Cell Surface Markers and May Explain the Induction of Tolerance by Kidney Allografts
N. Oh, M. Tonsho, D. Ndishabandi, R. Colvin, J. Madsen, A. Alessandrini.
Massachusetts General Hospital, Boston, MA.
Achieving tolerance in heart allografts is an important area of research as the need for heart transplantations increase. Recent studies in non-human primates (NHPs) have…
2015 American Transplant Congress
Intra-Allograft Common Rejection Module (CRM) Expression in Kidney Transplants Diagnoses Acute Rejection and Predicts Long Term Graft Prognosis
Y. Ng, S. Roedder, O. Bestard, T. Sigdel, S.-C. Hsieh, M. Sarwal.
Surgery, UC San Francisco, San Francisco, CA.
Background: Previous studies with cross-organ transcriptional analysis of 794 allograft biopsies from kidney, liver, heart and lung transplant patients identified a common rejection module (CRM)…